News
The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...
Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
4d
Investor's Business Daily on MSNRFK Jr. Just Did The Unexpected. He Helped Moderna.Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
The decision to cancel the Moderna contracts, undoubtedly driven by anti-vaccine crusader and HHS Secretary Robert F. Kennedy, Jr., puts the entire nation at risk, as does this administration’s ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results